AbbVie Financials - Benzinga

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$260.68

0.690.27%

Ult. Agg.: Sep 2, 10:05 AM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

AbbVie Financials

AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share

Benzinga Newsdesk

PRO
Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est

AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.

Benzinga Newsdesk

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Evette Mitkov

PRO
CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est

AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..

Benzinga Newsdesk

PRO
AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate

AbbVie (NYSE:ABBV) reported quarterly earnings of $3.65 per share which beat the analyst consensus estimate of $3.60 by 1.39 percent. This is a 22.9 percent increase over earnings of $2.97 per share from the same period

Benzinga Newsdesk

PRO
AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved